NCT00141375
Completed
Phase 3
An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.
ConditionsNeuropathic Pain
DrugsPregabalin
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Neuropathic Pain
- Sponsor
- Pfizer
- Enrollment
- 132
- Locations
- 1
- Primary Endpoint
- Safety and Efficacy
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.
- •Must have received study medication under double-blind conditions.
Exclusion Criteria
- •Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.
Outcomes
Primary Outcomes
Safety and Efficacy
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.PainNCT00141362Pfizer325
Completed
Phase 3
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.NeuralgiaNCT00150436Pfizer276
Terminated
Phase 3
Pregabalin Trial In HIV Neuropathic PainHIV-1 InfectionNeuropathic PainNCT01145417Pfizer's Upjohn has merged with Mylan to form Viatris Inc.217
Completed
Phase 3
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral NeuropathyDiabetic Neuropathy, PainfulNCT00553280Pfizer's Upjohn has merged with Mylan to form Viatris Inc.123
Completed
Phase 3
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With FibromyalgiaFibromyalgiaNCT00830128Pfizer's Upjohn has merged with Mylan to form Viatris Inc.106